

DACC TUDOUCU ENTITY (DTC) INICTITUTION INFORMATION

Subrecipient Letter of Intent or Commitment Form

PASS-THROUGH ENTITY (F	TE) INS	STITUTION IN	FURIVIATION							
PTE PI										
PTE Institution										
Prime Sponsor										
Project Title										
SUBRECIPIENT INSTITUTIO	N INFO	RMATION								
Institution										
FDP Expanded Clearinghouse Profile url										
PI Name					eRA	eRA Commons				
PI Phone				PI E-	E-Mail					
Project Period										
Performance Site Address	Performance Site Congressional District #									
Direct Costs	F&A Costs				Tota			Total Costs		
SUBRECIPIENT CONTACTS										
Administrative							E-Ma	il		
							Phon	e		
Authorized Official							E-Ma	il		
							Phon	e		
		YES/NO	APPROVAL D	ATE OR PEND	ING			YES/NO	APPROVA	AL DATE OR PENDING
Human Subjects						Recombinant dNA				
Vertebrate Animals						Program Income				
Human Embryonic Stem Cells						Cost Sharing				
Select Agents										

In signing below and offering to participate in this research program, the Subrecipient Institution certifies that they:

- nor their principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from receiving funds
 from any federal department or agency and are not delinquent on any federal debt;
- are in compliance with the Drug Free Workplace Act of 1988;
- are in compliance with U.S. Code, Section 1352, restrictions on the use of federal funds for the purpose of lobbying;
- have filed annually with the Office of Scientific Integrity a Public Health Service (PHS) form 6349 governing Misconduct in Science;
- have filed with Department of Health and Human Services (DHHS) compliance offices certification forms governing Civil Rights (441), Handicapped Individuals (641), Sex Discrimination (639-A), and Age Discrimination (680);
- · are in compliance with PHS policy governing Program Income;
- have established policies in compliance with 45 CFR Part 46, Subpart A (protection of human subjects); the Animal Welfare Act (PL-89-544 as amended) and the Health Research Exchange Act of 1985 (Public Law 158);
- are in compliance with the National Institutes of Health (NIH) guidelines regarding human pluripotent stem cell research, transplantation of fetal tissue, recombinant DNA and human gene transfer research, and inclusion of women, children & minorities in research;
- have implemented and are enforcing a written policy of financial conflict of interest compliant with the:
 - o PHS provisions of 42 CFR Part 50, Subpart F and 45 CFR Part 94
 - o Department of Energy (DOE) Interim Conflict of Interest Policy Requirements for Financial Assistance
 - National Science Foundation (NSF) policy on conflicts of interest. All individuals responsible for the design, conduct or reporting of research for the proposal have made the required disclosures to the subrecipient's institutional official in accordance with the subrecipient's policy. Subrecipient shall report any financial conflict of interest to PTE's designated representative. Such report shall be made before expenditure of funds authorized by the sponsor and within 30 days of any subsequently identified financial conflict of interest

necessary inter-institutional agreement consistent with that policy. binding upon the Pass-Though Entity. All terms and conditions betw	Any terms or rates included in the proposal described herein are not een the parties will be outlined in a separate formal Agreement
SUBRECIPIENT INSTITUTIONAL OFFICIAL:	
Name and Title	Signature/Date

This proposal has been reviewed and approved by the appropriate official(s) of Subrecipient and certified to its accuracy and completeness. The appropriate programmatic and administrative personnel of Subrecipient involved in this application are aware of the prime awarding agency's policies, agree to accept the obligation to comply with award terms, conditions, and certifications, and is prepared to establish the